• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

宿主对新型冠状病毒的抵抗力。

Host resilience to emerging coronaviruses.

作者信息

Jamieson Amanda M

机构信息

Department of Microbiology and Immunology, Brown University, Providence, RI, USA.

出版信息

Future Virol. 2016 Jul;11(7):529-534. doi: 10.2217/fvl-2016-0060. Epub 2016 Jul 1.

DOI:10.2217/fvl-2016-0060
PMID:32201496
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7079962/
Abstract

Recently, two coronaviruses, severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus, have emerged to cause unusually severe respiratory disease in humans. Currently, there is a lack of effective antiviral treatment options or vaccine available. Given the severity of these outbreaks, and the possibility of additional zoonotic coronaviruses emerging in the near future, the exploration of different treatment strategies is necessary. Disease resilience is the ability of a given host to tolerate an infection, and to return to a state of health. This review focuses on exploring various host resilience mechanisms that could be exploited for treatment of severe acute respiratory syndrome coronavirus, Middle East respiratory syndrome coronavirus and other respiratory viruses that cause acute lung injury and acute respiratory distress syndrome.

摘要

最近,两种冠状病毒,即严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒,出现并导致人类患上异常严重的呼吸道疾病。目前,缺乏有效的抗病毒治疗方案或可用疫苗。鉴于这些疫情的严重性,以及近期可能出现更多人畜共患冠状病毒的可能性,探索不同的治疗策略是必要的。疾病恢复力是指特定宿主耐受感染并恢复健康状态的能力。本综述着重探讨各种宿主恢复力机制,这些机制可用于治疗严重急性呼吸综合征冠状病毒、中东呼吸综合征冠状病毒以及其他导致急性肺损伤和急性呼吸窘迫综合征的呼吸道病毒。

相似文献

1
Host resilience to emerging coronaviruses.宿主对新型冠状病毒的抵抗力。
Future Virol. 2016 Jul;11(7):529-534. doi: 10.2217/fvl-2016-0060. Epub 2016 Jul 1.
2
Broad-spectrum coronavirus antiviral drug discovery.广谱冠状病毒抗病毒药物的发现。
Expert Opin Drug Discov. 2019 Apr;14(4):397-412. doi: 10.1080/17460441.2019.1581171. Epub 2019 Mar 8.
3
Human and novel coronavirus infections in children: a review.儿童人感染和新型冠状病毒感染:综述。
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
4
Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.阿贝尔森激酶抑制剂是严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒融合的强效抑制剂。
J Virol. 2016 Sep 12;90(19):8924-33. doi: 10.1128/JVI.01429-16. Print 2016 Oct 1.
5
Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection.通过TRIF的Toll样受体3信号传导有助于对严重急性呼吸综合征冠状病毒感染产生保护性先天免疫反应。
mBio. 2015 May 26;6(3):e00638-15. doi: 10.1128/mBio.00638-15.
6
A comparative review of pathogenesis and host innate immunity evasion strategies among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV).严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2)、严重急性呼吸综合征冠状病毒 (SARS-CoV) 和中东呼吸综合征冠状病毒 (MERS-CoV) 的发病机制和宿主固有免疫逃避策略的比较综述。
Arch Microbiol. 2021 Jul;203(5):1943-1951. doi: 10.1007/s00203-021-02265-y. Epub 2021 Mar 7.
7
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.SARS-CoV-2 及其他人类致病冠状病毒的抗病毒药物和可用药靶的现状。
Drug Resist Updat. 2020 Dec;53:100721. doi: 10.1016/j.drup.2020.100721. Epub 2020 Aug 26.
8
Evaluating the potential impact of targeted vaccination strategies against severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks in the healthcare setting.评估针对严重急性呼吸综合征冠状病毒(SARS-CoV)和中东呼吸综合征冠状病毒(MERS-CoV)在医疗机构爆发的针对性疫苗接种策略的潜在影响。
Theor Biol Med Model. 2019 Oct 7;16(1):16. doi: 10.1186/s12976-019-0112-6.
9
Coronaviruses: severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus in travelers.冠状病毒:旅行者中的严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒
Curr Opin Infect Dis. 2014 Oct;27(5):411-7. doi: 10.1097/QCO.0000000000000089.
10
A molecular arms race between host innate antiviral response and emerging human coronaviruses.宿主固有抗病毒反应与新兴人类冠状病毒之间的分子军备竞赛。
Virol Sin. 2016 Feb;31(1):12-23. doi: 10.1007/s12250-015-3683-3. Epub 2016 Jan 15.

引用本文的文献

1
Integrin-ECM interactions and membrane-associated Catalase cooperate to promote resilience of the Drosophila intestinal epithelium.整合素-细胞外基质相互作用和膜相关的过氧化氢酶协同作用促进果蝇肠道上皮细胞的弹性。
PLoS Biol. 2022 May 6;20(5):e3001635. doi: 10.1371/journal.pbio.3001635. eCollection 2022 May.
2
Cellular nucleic acid-binding protein is essential for type I interferon-mediated immunity to RNA virus infection.细胞核酸结合蛋白对于 I 型干扰素介导的 RNA 病毒感染免疫至关重要。
Proc Natl Acad Sci U S A. 2021 Jun 29;118(26). doi: 10.1073/pnas.2100383118.
3
Differential Diagnosis and Hospital Emergency Management for Fastlane Treatment of Central Nervous System Infection Under the COVID-19 Epidemic in Changsha, China.中国长沙新冠疫情期间中枢神经系统感染快速通道治疗的鉴别诊断与医院应急管理
Front Neurol. 2020 Oct 20;11:555202. doi: 10.3389/fneur.2020.555202. eCollection 2020.
4
Biophysical analysis of SARS-CoV-2 transmission and theranostic development via N protein computational characterization.通过 N 蛋白计算特性分析对 SARS-CoV-2 传播的生物物理分析和治疗开发。
Biotechnol Prog. 2021 Mar;37(2):e3096. doi: 10.1002/btpr.3096. Epub 2020 Nov 9.
5
SARS-CoV-2 and Dentistry-Review.严重急性呼吸综合征冠状病毒2与牙科——综述
Eur J Dent. 2020 Dec;14(S 01):S130-S139. doi: 10.1055/s-0040-1716438. Epub 2020 Sep 15.

本文引用的文献

1
Acute respiratory distress syndrome.急性呼吸窘迫综合征
Lancet. 2016 Nov 12;388(10058):2416-2430. doi: 10.1016/S0140-6736(16)00578-X. Epub 2016 Apr 28.
2
Emerging infectious diseases: Focus on infection control issues for novel coronaviruses (Severe Acute Respiratory Syndrome-CoV and Middle East Respiratory Syndrome-CoV), hemorrhagic fever viruses (Lassa and Ebola), and highly pathogenic avian influenza viruses, A(H5N1) and A(H7N9).新发传染病:聚焦新型冠状病毒(严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒)、出血热病毒(拉沙病毒和埃博拉病毒)以及高致病性禽流感病毒A(H5N1)和A(H7N9)的感染控制问题。
Am J Infect Control. 2016 May 2;44(5 Suppl):e91-e100. doi: 10.1016/j.ajic.2015.11.018.
3
Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation.拓扑异构酶1抑制作用可抑制炎症基因并保护机体免受炎症导致的死亡。
Science. 2016 May 27;352(6289):aad7993. doi: 10.1126/science.aad7993. Epub 2016 Apr 28.
4
Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia.沙特阿拉伯王国一家冠状病毒转诊中心中东呼吸综合征冠状病毒(MERS-CoV)感染患者的治疗结果。
BMC Infect Dis. 2016 Apr 21;16:174. doi: 10.1186/s12879-016-1492-4.
5
Disease-specific dynamic biomarkers selected by integrating inflammatory mediators with clinical informatics in ARDS patients with severe pneumonia.通过整合炎症介质与临床信息学在重症肺炎急性呼吸窘迫综合征患者中筛选出的疾病特异性动态生物标志物。
Cell Biol Toxicol. 2016 Jun;32(3):169-84. doi: 10.1007/s10565-016-9322-4. Epub 2016 Apr 19.
6
Tracking Resilience to Infections by Mapping Disease Space.通过绘制疾病空间来追踪对感染的抵抗力
PLoS Biol. 2016 Apr 18;14(4):e1002436. doi: 10.1371/journal.pbio.1002436. eCollection 2016 Apr.
7
Editorial overview: Emerging viruses: Interspecies transmission.社论概述:新兴病毒:跨物种传播
Curr Opin Virol. 2016 Feb;16:v-vi. doi: 10.1016/j.coviro.2016.03.005.
8
Early initiation of extracorporeal membrane oxygenation improves survival in adult trauma patients with severe adult respiratory distress syndrome.早期启动体外膜肺氧合可提高患有严重成人呼吸窘迫综合征的成年创伤患者的生存率。
J Trauma Acute Care Surg. 2016 Aug;81(2):236-43. doi: 10.1097/TA.0000000000001068.
9
Mapping the Specific Amino Acid Residues That Make Hamster DPP4 Functional as a Receptor for Middle East Respiratory Syndrome Coronavirus.确定使仓鼠二肽基肽酶4(DPP4)作为中东呼吸综合征冠状病毒受体发挥功能的特定氨基酸残基
J Virol. 2016 May 12;90(11):5499-5502. doi: 10.1128/JVI.03267-15. Print 2016 Jun 1.
10
Host-directed therapies for antimicrobial resistant respiratory tract infections.针对耐抗菌药物呼吸道感染的宿主导向疗法。
Curr Opin Pulm Med. 2016 May;22(3):203-11. doi: 10.1097/MCP.0000000000000271.